

January 7, 2021



# Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021.

The presentation will be available on Monday, January 11, 2021 at 6:00am EST and may be accessed at the "Events & Presentations" section of the Company's website at <https://www.kezarlifesciences.com/investors/news-events>. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

## About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via selective targets. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities. For more information, visit [www.kezarlifesciences.com](http://www.kezarlifesciences.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210107005804/en/>

Celia Economides  
SVP, Strategy & External Affairs  
[IR@kezarbio.com](mailto:IR@kezarbio.com)

Argot Partners  
(212)-600-1902  
[kezar@argotpartners.com](mailto:kezar@argotpartners.com)

Source: Kezar Life Sciences, Inc.